Dr. Roussos Torres on the Potential for Immunotherapy in HER2+ Breast Cancer – OncLive
OncLive |
Dr. Roussos Torres on the Potential for Immunotherapy in HER2+ Breast Cancer
OncLive Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients with HER2-positive breast cancer. Currently, most preclinical work and clinical trials of … |
